Next Generation Sequencing

OncoPlus (FFPE, Bone  Marrow, Peripheral Blood)

The OncoPlus panel is a targeted next generation sequencing (NGS) assay that has the capability to cover 1,213 cancer-related genes for personalized assessments of both solid tumors and hematological malignancies. Variant calling in 147 genes shown below are reportable for clinical patient care:

ARID1A, ARID2, ASXL1, ATM, ATR, ATRX, AXL, B2M, BAP1, BCOR, BCORL1, BIRC3, BLM, BRAF, BRCA1, BRCA2, BTK, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CDH1, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DICER1, DNMT3A, EGFR, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA1, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3F3A, HDAC2, HIST1H3B, HIST1H3C, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDM6A, KDR, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MET, MLH1, MLH3, MPL, MRE11A, MSH2, MSH6, MTOR, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, PALB2, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51, RB1, RET, RUNX1, SDHB, SDHC, SETBP1, SF3B1, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SRSF2, STAG2, STK11, TERT (promoter only), TET2, TP53, TSC1, TSC2, U2AF1, VHL, WT1, and ZRSR2. 

Copy number variation detection (gene-level gain or loss) for 136 autosomal genes. Detection of lung cancer-related gene fusions (ALK, RET, and ROS1). Detection of a specific rearrangement in EGFR (VIII variant) 

For more details and ordering, please click here.

OncoScreen (ST2.0, Extended RAS Assay)

The OncoScreen ST2.0 assay is designed to sequence hot-spot mutational regions of 50 clinically relevant genes that are commonly mutated in cancer for the purpose of identifying somatic mutations (substitutions and insertions/deletions). Mutations in these 50 genes are linked to many types of cancers, including lung, colorectal, gastric, thyroid, ovarian cancer, melanoma and myeloid malignancies.Mutations with known clinical significance and/or those deemed to be pathogenically related to the biology of each patient’s tumor are reported, and this personalized mutational profile may be useful fordiagnosis, prognosis, therapy selection, clinical trials options and for translational research.

For more details and ordering, please click here.

OncoHeme

This assay is designed to sequence the full coding sequence (or nearly full coding sequence) of 53 clinically relevant genes that are commonly mutated in a variety of hematopoietic neoplasms (mainly acute myeloid leukemia and myelodysplastic and myeloproliferative syndromes) for the purpose of identifying somatic mutations (substitutions and insertions/deletions). Mutations with known clinical significance and/or those deemed to be pathogenically related to the biology of each patient’s tumor are reported, and this personalized mutational profile may be useful for prediction of prognosis or response to targeted therapies.

For more details and ordering, please click here.

APOL1

This is a next-generation sequencing assay for the qualitative detection of two APOL1 nephropathy risk alleles (G1 and G2) in peripheral blood. This test is indicated for African-Americans with a clinical risk or family history of kidney disease and African-Americans being evaluated as living kidney donor. Results from this test are intended for use as an adjunct to existing clinical information.

For more details and ordering, please click here.

Lung Fusion (FFPE, Cytology Smear)

This test is intended for the detection of clinically relevant ALK, RET and ROS1 fusion genes in lung cancer samples with at least 10 percent tumor cells and adequate RNA. The assay is designed for detection of specific isoforms present in ~95-98% of ALK, RET and ROS1 fusion-containing specimens, with additional ability to detect the presence of novel isoforms.  When novel isoforms are suspected, additional follow-up testing will be recommended.

For more details and ordering, please click here.

CEBPA

Initial evaluation of acute myeloid leukemia, both for assigning an appropriate diagnostic subclassification and as an aid for determining prognosis.

For more details and ordering, please click here.